Evoke Pharma/ US30049G2030 /
2024-05-17 4:59:40 PM | Chg. -0.03 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.48USD | -5.89% | 100 Turnover: 47.90 |
-Bid Size: - | -Ask Size: - | 0.48 | 0.48 |
GlobeNewswire
05-16
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care ...
GlobeNewswire
04-17
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastropar...
GlobeNewswire
03-21
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief ...
GlobeNewswire
03-07
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
GlobeNewswire
02-09
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
GlobeNewswire
2023-11-14
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
GlobeNewswire
2023-10-31
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healt...
GlobeNewswire
2023-10-18
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclo...
GlobeNewswire
2022-03-10
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
GlobeNewswire
2022-03-01
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
GlobeNewswire
2022-02-02
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
GlobeNewswire
2022-01-04
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
GlobeNewswire
2021-11-03
Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021
GlobeNewswire
2021-10-20
Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
GlobeNewswire
2021-09-29
Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innova...
GlobeNewswire
2021-09-01
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference